| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
155,668 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,250,478 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
162,341 |
|
|
| Total
Value |
$5,250,478 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2023-06-02 |
40,493 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
180 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2008-12-11 |
4 |
OE |
$8.48 |
$42,400 |
D/D |
5,000 |
20,301 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2003-12-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
200 |
20,480 |
|
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,562 |
20,562 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2021-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,889) |
20,562 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2013-07-10 |
4 |
S |
$1.72 |
$5,854 |
D/D |
(3,403) |
20,644 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-06 |
4 |
AS |
$93.32 |
$214,916 |
D/D |
(2,303) |
20,761 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,076 |
20,885 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2004-12-28 |
4 |
OE |
$9.00 |
$9,000 |
D/D |
1,000 |
20,988 |
|
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
D |
$3.94 |
$2,340 |
D/D |
(594) |
21,006 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,058 |
21,490 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-08-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
325 |
21,506 |
|
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,375 |
21,600 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-03 |
4 |
D |
$93.95 |
$214,488 |
D/D |
(2,283) |
23,064 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-11-09 |
4 |
S |
$90.61 |
$1,812,206 |
D/D |
(20,000) |
23,100 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2021-06-17 |
4 |
AS |
$30.52 |
$95,795 |
D/D |
(3,139) |
23,129 |
0 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-06-02 |
4 |
D |
$90.72 |
$163,387 |
D/D |
(1,801) |
23,303 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2013-02-20 |
4 |
S |
$1.96 |
$25,054 |
D/D |
(12,780) |
24,047 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2013-06-09 |
4 |
D |
$1.86 |
$2,111 |
D/D |
(1,135) |
24,357 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-11-03 |
4 |
OE |
$9.25 |
$231,250 |
D/D |
25,000 |
25,000 |
|
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-05-15 |
4 |
D |
$91.50 |
$157,563 |
D/D |
(1,722) |
25,104 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-01 |
4 |
AS |
$94.50 |
$472,500 |
D/D |
(5,000) |
25,347 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2012-06-07 |
4 |
A |
$3.67 |
$29,999 |
D/D |
8,174 |
25,492 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-02-25 |
4 |
D |
$15.58 |
$67,259 |
D/D |
(4,317) |
25,510 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,848 |
26,268 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,200 |
26,671 |
0 |
- |
|
180 Records found
|
|
Page 3 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
